What question did this study set out to answer?

This research aims to compare the drug survival rates of adalimumab and infliximab in patients with hidradenitis suppurativa.

Drug Survival of Adalimumab and Infliximab in Hidradenitis Suppurativa

View Full Paper

Ask AI

Bookmark

Authors

The study examines drug survival of adalimumab and infliximab in hidradenitis suppurativa, indicating important therapeutic implications.

This research aims to compare the drug survival rates of adalimumab and infliximab in patients with hidradenitis suppurativa.
Data collection on drug survival rates of adalimumab and infliximab in hidradenitis suppurativa patients
Use of patient records to analyze therapeutic outcomes
Results will provide insights on the effectiveness and durability of adalimumab compared to infliximab
Specific numerical data and event rates are not disclosed due to restrictions

Shrestha et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark